Профілі користувачів для пошукового запитаBoris Sepesi
 |
Boris Sepesi
Associate Professor
Підтверджена електронна адреса в mdanderson.org
Цитовано в 6069 джерелах |
[HTML][HTML]Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non–small-cell lung cancer: long-term results of a multi …
…,BD Kavanagh, AS Tsao,BSepesi… - Journal of Clinical …, 2019 - ncbi.nlm.nih.gov
PURPOSE Our previously published findings reported that local consolidative therapy (LCT)
with radiotherapy or surgery improved progression-free survival (PFS) and delayed new …
with radiotherapy or surgery improved progression-free survival (PFS) and delayed new …
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line …
Background Evidence from retrospective studies suggests that disease progression after first-line
chemotherapy for metastatic non-small-cell lung cancer (NSCLC) occurs most often at …
chemotherapy for metastatic non-small-cell lung cancer (NSCLC) occurs most often at …
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
Ipilimumab improves clinical outcomes when combined with nivolumab in metastatic non-small
cell lung cancer (NSCLC), but its efficacy and impact on the immune microenvironment …
cell lung cancer (NSCLC), but its efficacy and impact on the immune microenvironment …
Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma
…, LY Kong,AB Heimberger, J de Groot,BSepesi… - Nature medicine, 2020 - nature.com
Immune checkpoint therapy with anti-CTLA-4 and anti-PD-1/PD-L1 has revolutionized the
treatment of many solid tumors. However, the clinical efficacy of immune checkpoint therapy is …
treatment of many solid tumors. However, the clinical efficacy of immune checkpoint therapy is …
Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR …
8504 Background: Neoadjuvant immune checkpoint inhibitors (ICIs) induce major
pathologic response (MPR) rates of 20 to 45% in resected NSCLCs. We report the results of …
pathologic response (MPR) rates of 20 to 45% in resected NSCLCs. We report the results of …
[HTML][HTML]Comprehensive T cell repertoire characterization of non-small cell lung cancer
Immunotherapy targeting T cells is increasingly utilized to treat solid tumors including non-small
cell lung cancer (NSCLC). This requires a better understanding of the T cells in the …
cell lung cancer (NSCLC). This requires a better understanding of the T cells in the …
[HTML][HTML]The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)
Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small cell
lung cancer (NSCLC) accounting for over 85% of all cases. Until recently, chemotherapy – …
lung cancer (NSCLC) accounting for over 85% of all cases. Until recently, chemotherapy – …
Are endoscopic therapies appropriate for superficial submucosal esophageal adenocarcinoma? An analysis of esophagectomy specimens
BSepesi, TJ Watson, D Zhou, M Polomsky… - Journal of the American …, 2010 - Elsevier
Background Endoscopic resection and ablation have advanced the treatment of intramucosal
esophageal adenocarcinoma and have been promoted as definitive therapy for selected …
esophageal adenocarcinoma and have been promoted as definitive therapy for selected …
Diets enriched in foods with high antioxidant activity reverse age-induced decreases in cerebellar β-adrenergic function and increases in proinflammatory cytokines
C Gemma,MH Mesches,BSepesi, K Choo… - Journal of …, 2002 - Soc Neuroscience
Antioxidants and diets supplemented with foods high in oxygen radical absorbance capacity
(ORAC) reverse age-related decreases in cerebellar β-adrenergic receptor function. We …
(ORAC) reverse age-related decreases in cerebellar β-adrenergic receptor function. We …
[HTML][HTML]Programmed death-ligand 1 heterogeneity and its impact on benefit from immune checkpoint inhibitors in NSCLC
Introduction Programmed death-ligand 1 (PD-L1) expression may vary in different disease
sites and at different time points of the disease course. We aimed to investigate PD-L1 …
sites and at different time points of the disease course. We aimed to investigate PD-L1 …